ArticleMedicine2025
Metformin mitigates cisplatin-induced premature ovarian insufficiency via Sirt1/Nrf2 activation.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Impact of Oxidative Stress Imbalance on Ovarian Function and Its Mechanisms.International journal of general medicine · 2026Review
- Gut microbiota-derived butyrate and the SIRT1/FoxO1 axis: epigenetic-metabolic regulation of ovarian function in premature ovarian insufficiency-a comprehensive review.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremature ovarian insufficiency (POI) occurs in young women who receive chemotherapy, with cisplatin being the known culprit. Cisplatin-induced ovarian damage associated with POI results from oxidative stress. Metformin, a widely prescribed drug for type 2 diabetes, plays an important role in the mitigation of oxidative stress. However, the precise mechanism through which metformin protects against cisplatin-induced POI remains unclear. Hence, this study aimed to investigate the protective effects of metformin against cisplatin-induced granulosa cell (GCs) damage and explore the underlying anti-oxidative stress mechanisms.
methodsIn this study, an in vitro POI model was established using cisplatin-treated human GCs. Metformin pretreatment was used to assess the effects of metformin on damaged GCs. Cell viability and hormone levels were measured using CCK8 and enzyme-linked immunosorbent assay, respectively. The mechanisms of oxidative stress repair by metformin were evaluated using flow cytometry, western blot analysis, and quantitative real-time polymerase chain reaction.
resultsMetformin pretreatment significantly enhanced GC viability, reduced apoptosis, decreased reactive oxygen species levels, improved mitochondrial function, and increased superoxide dismutase activity. Additionally, metformin upregulated the expression of Bcl-2, Sirt1, and Nrf2, while downregulating Bax, indicating its protective role through the activation of the Sirt1/Nrf2 signaling pathway.
conclusionMetformin may serve as a promising therapeutic agent to prevent POI by mitigating oxidative stress and apoptosis.
Indexed as
Identifiers
41305781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.